Pay in 4 interest-free payments of $6.58 Learn more
Ships within 48 hours · Estimated delivery Sep 27 - Oct 2
Pictured: Sign at Pfizers headquarters in New York/iStock, JHVEPhoto Pfizer on Friday said it is scrapping an investigational twice-daily oral Glucagon-like peptide-1 receptor agonist candidate after topline data from a Phase IIb trial of obese patients without type 2 diabetes showed high rates of adverse events
Start your intake Common Local and Injection-Site Reactions Local reactions at the injection site are the most frequently reported adverse effects
Clean both vial stoppers
If left unaddressed, a deficiency can result in severe complications, including irreversible nerve damage or memory impairment, making early diagnosis and ongoing treatment essential
Systematic review finds overlapping reviews were not mentioned in every other overview
Disease primers
